Latest News

Janssen receives EMA committee recommendation to market Symtuza for HIV

Janssen-Cilag International (Janssen) has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending...

Janssen receives EMA committee recommendation to market Symtuza for HIV

Lilly and Nektar partner to develop new immunological therapy NKTR-358

Lilly and Nektar partner to develop new immunological therapy NKTR-358

Mitsubishi Tanabe Pharma to buy NeuroDerm for $1.1bn

Japan’s Mitsubishi Tanabe Pharma (MTPC) has entered a new definitive agreement to acquire all of the outstanding shares of Israel-based pharmaceutical company NeuroDerm for $1.1bn in...

Mitsubishi Tanabe Pharma to buy NeuroDerm for $1.1bn

NICE approves new tolerable drug carflizomib for multiple myeloma patients on NHS

NICE approves new tolerable drug carflizomib for multiple myeloma patients on NHS

Recipharm and LIDDS set up prostate cancer drug development facility in Sweden

Recipharm, a Swedish contract development and manufacturing organisation (CDMO), and LIDDS have jointly established an industrial manufacturing line to develop new prostate cancer drug, Liproca...

Recipharm and LIDDS set up prostate cancer drug development facility in Sweden

EMA’s CHMP recommends Merck and Pfizer's cancer drug avelumab for approval

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Merck and Pfizer's avelumab (BAVENCIO) as...

EMA’s CHMP recommends Merck and Pfizer's cancer drug avelumab for approval

Deals this week: Hugel, Guangdong Zhongsheng Pharmaceutical, Valeant Pharmaceuticals International

South Korean pharmaceutical company Hugel has announced the private placement of 985,217 common stock shares priced at KRW360,001.9 ($316.2) a share to raise KRW354.68bn ($311.52m) in gross...

Deals this week: Hugel, Guangdong Zhongsheng Pharmaceutical, Valeant Pharmaceuticals International

M&As this week: Northeast Pharmaceutical Group, Principia SGR, Commelina

Chinese pharmaceutical company Northeast Pharmaceutical Group plans to acquire 60% stake in a medicine company based in Dandong, China, through its subsidiary for CNY3.9m...

M&As this week: Northeast Pharmaceutical Group, Principia SGR, Commelina

NICE recommends Teva’s Cinqaero to treat severe eosinophilic asthma

The UK National Institute for Health and Care Excellence (NICE) has recommended Teva Pharmaceutical Industries’ Cinqaero (reslizumab) for the treatment of patients with severe eosinophilic...

NICE recommends Teva’s Cinqaero to treat severe eosinophilic asthma

Ablynx and Sanofi collaborate for nanobody-based inflammatory disease treatments

Belgian biopharmaceutical company Ablynx has entered a research collaboration and global exclusive licensing agreement with French firm Sanofi to develop and commercialise...

Ablynx and Sanofi collaborate for nanobody-based inflammatory disease treatments

GSK to invest additional £140m at UK manufacturing sites

GlaxoSmithKline (GSK) is set to invest more than £140m at its production facilities in the UK to improve the efficiency and competitiveness of its manufacturing...

GSK to invest additional £140m at UK manufacturing sites

Elsalys Biotech and DKFZ collaborate to develop ELB021 in B-Cell leukaemia

Elsalys Biotech has entered a preclinical collaboration with German cancer research institute DKFZ to initiate the development of ELB021 in B-Cell leukaemia, under European Union (EU)...

Elsalys Biotech and DKFZ collaborate to develop ELB021 in B-Cell leukaemia

Gilead’s Vosevi receives FDA approval for re-treatment of chronic HCV

Gilead’s Vosevi receives FDA approval for re-treatment of chronic HCV

Takeda and Prana to research neurodegeneration treatment for Parkinson's disease

Takeda Pharmaceuticals International has entered a new research collaboration to study the ability of Prana Biotechnology’s investigational movement disorders compound, PBT434, to slow down...

Takeda and Prana to research neurodegeneration treatment for Parkinson's disease

Valeant to sell Obagi medical products business for $190m

Valeant Pharmaceuticals International has entered an agreement through certain affiliates to divest its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition...

Valeant to sell Obagi medical products business for $190m

Research team discovers epithelial cells in eyes can prevent spread of Ebola

Research team discovers epithelial cells in eyes can prevent spread of Ebola

UDG Healthcare to acquire Cambridge BioMarketing for up to $35m

International healthcare services provider UDG Healthcare has agreed to acquire US-based healthcare communications business Cambridge BioMarketing for a total consideration of up to...

UDG Healthcare to acquire Cambridge BioMarketing for up to $35m

FDA asks for additional data to approve Evenity in US

Pharmaceutical companies Amgen and UCB have received a Complete Response Letter from the US Food and Drug Administration (FDA) for Evenity, a treatment for postmenopausal women with...

FDA asks for additional data to approve Evenity in US

Roche’s Ocrevus receives TGA approval for RMS and PPMS treatment in Australia

Roche’s Ocrevus receives TGA approval for RMS and PPMS treatment in Australia

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

Janssen Biotech’s Tremfya receives FDA approval for plaque psoriasis treatment

The US Food and Drug Administration (FDA) has granted approval for Janssen Biotech’s Tremfya (guselkumab) to treat adults with moderate-to-severe plaque psoriasis who are candidates for...

Janssen Biotech’s Tremfya receives FDA approval for plaque psoriasis treatment
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_946450448